ASH

CAR-T cell therapy and bispecifics in the treatment of lymphoma: Updates from ASH 2022 Prof. Swaminathan Iyer (University of Texas MD Anderson Cancer Center) reviews the latest data around CAR-T cell therapy and bispecific antibodies presented at ASH 2022. Further information: Abstract 655 entitled ‘Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy […]

The role of transplant and biologics in mantle cell lymphoma In the first of two updates from ASH 2022, Swaminathan Iyer (University of Texas MD Anderson Cancer Center) provides an overview of the plenary session presented by Dr Martin Dreyling at ASH 2022, discussing the role of transplant and biologics in mantle cell lymphoma. In […]

Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA)  discusses pacritinib in the potential treatment of myelofibrosis and severe thrombocytopenia. Treatment options for myelofibrosis and severe thrombocytopenia are restricted due to high occurrences of JAK inhibitor-related thrombocytopenia. The abstract entitled ‘PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s […]

María-Victoria Mateos (University of Salamanca, Salamanca, Spain), leading expert in mulitple myeloma, shared her thoughts on the current challenges in CAR-T cell therapy and the strategies being investigated to address them.  CAR-T therapy has introduced a new treatment modality to the triple-class refractory patient population, who had minimal effective treatment options previously. Disclosures: María-Victoria Mateos […]

We were delighted to speak with María-Victoria Mateos (University of Salamanca, Salamanca, Spain) about the recent updates in bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma. Disclosures: María-Victoria Mateos discloses the following –  Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees […]